Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geneart establishes new subsidiary in west coast of US
According to the company, the newly founded subsidiary, Geneart Inc, is located in the San Francisco Bay Area, at the heart of one of the largest biotech clusters
According to the company, the newly founded subsidiary, Geneart Inc, is located in the San Francisco Bay Area, at the heart of one of the largest biotech clusters
These new findings further support previous positive results announced for this vaccine in June 2008. The data were derived from a histopathological analysis of tissues samples collected in
The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of
Under the terms of the Agreement, Cura will continue to be responsible for manufacturing, regulatory, medical, clinical development, pricing and distribution for the product while Medivisor is responsible
The findings demonstrate that microRNAs have the potential to be used as clinical biomarkers for a wide range of indications in cancer and women’s health, the company said.
According to the company, the system fingerprints infection-causing bacteria using automated DNA sequencing, stores the resulting DNA sequences in a central database and analyzes the results using proprietary
This approval follows the earlier approval of the name change by the board of directors and the shareholders of the company. Tony Jimenez, CEO of Fountain Healthy Aging,
Under the modified agreement, Medistem will receive $1 million cash and the return of 560,000 shares of Medistem common stock (valued at $700,000 based on the closing price
BioSpecifics has modified its previously announced agreement to lower future royalties’ payable on net sales of its injectable collagenase, Xiaflex, for Peyronie’s disease. The company said that it
The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund, Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital and Western Technology